Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Explore the groundbreaking Phase I trial of hu3S193, a humanized monoclonal antibody targeting Lewis-Y antigen in epithelial cancers. Learn about its precision targeting, pharmacokinetics, and future therapeutic potential.